{"nctId":"NCT00090220","briefTitle":"A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)","startDateStruct":{"date":"2004-06-16","type":"ACTUAL"},"conditions":["Healthy Adult Female Participants","Prevention","Papillomavirus Infection","Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18"],"count":3819,"armGroups":[{"label":"qHPV Vaccine in Base Study","type":"EXPERIMENTAL","interventionNames":["Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine"]},{"label":"Placebo in Base Study","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine","Biological: Comparator: Placebo"]}],"interventions":[{"name":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine","otherNames":[]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* No history of genital warts, vulvar intraepithelial neoplasia (VIN), or vaginal intraepithelial neoplasia (VaIN)\n* Not pregnant and agrees to use effective contraception through Month 7 of the study\n* Additional criteria applied\n\nExclusion Criteria:\n\n* Pregnant\n* Concurrently enrolled in a clinical study involving collection of cervical specimens\n* Previously received any HPV vaccine\n* History of severe allergic reaction that required medical intervention\n* Received any immune globulin or blood-derived products within 3 months prior to the first study injection\n* History of splenectomy, known immune disorders, or receiving immunosuppressives\n* Immunocompromised or diagnosed with human immunodeficiency virus (HIV) infection\n* Known thrombocytopenia or any coagulation disorders that could contraindicate intramuscular injections\n* History of recent or ongoing alcohol or drug abuse\n* Prior treatment for genital warts, VIN, or VaIN\n* History of cervical disease (ie, surgical treatment for cervical lesions)\n* Hysterectomy","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"24 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence Rate of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer","description":"The four HPV types were determined by polymerase chain reaction (PCR) testing. VIN = vulvar intraepithelial neoplasia; VaIN = vaginal intraepithelial neoplasia; AIS = adenocarcinoma in situ.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Vaccine- or Placebo-Related Serious Adverse Events (SAEs) in the Base Study","description":"An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or is an overdose. Vaccine-related SAEs are those deemed by the investigator to be definitely, probably, or possibly related to study vaccine.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Vaccine-Related SAEs After Vaccine Administration","description":"An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or is an overdose. Vaccine-related SAEs are those deemed by the investigator to be definitely, probably, or possibly related to study vaccine.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With an SAE Resulting in Death After Vaccine Administration","description":"An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or is an overdose.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Cumulative Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN) or Condyloma: Day 1 to Year 4","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Day 1 to Year 4, conditional on having been event-free at Day 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0006","spread":null},{"groupId":"OG001","value":"0.0124","spread":null}]}]}]},{"type":"PRIMARY","title":"Cumulative Incidence of HPV 6/11/16/18-related CIN or Condyloma: Year 4 to 8","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 4 to Year 8, conditional on having been event-free from Day 1 to Year 4. The analysis windows were cut at the exact time points, e.g., Year 4. Visits and events which occurred after Year 4 due to visit window or follow-up investigations are included in the Year 4 to Year 8 time interval.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]}]},{"type":"PRIMARY","title":"Cumulative Incidence of HPV 6/11/16/18-related CIN or Condyloma: Year 6 to 10","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 6 to Year 10, conditional on having been event-free from Day 1 to Year 6.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Day 1 to Year 4","description":"The four HPV types were determined by PCR testing.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Year 4 to 8","description":"The four HPV types were determined by PCR testing. The analysis windows were cut at the exact time points, e.g., Year 4. Visits and events which occurred after Year 4 due to visit window or follow-up investigations are included in the Year 4 to Year 8 time interval.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Year 6 to 10","description":"The four HPV types were determined by PCR testing.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 1 Month Postdose 3 in the Base Study","description":"Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"416.2","spread":null},{"groupId":"OG001","value":"437.4","spread":null},{"groupId":"OG002","value":"397.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"551.2","spread":null},{"groupId":"OG001","value":"595.1","spread":null},{"groupId":"OG002","value":"512.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2225.9","spread":null},{"groupId":"OG001","value":"2334.2","spread":null},{"groupId":"OG002","value":"2129.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"356.9","spread":null},{"groupId":"OG001","value":"393.1","spread":null},{"groupId":"OG002","value":"324.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 6 Months Postdose 3 in the Base Study","description":"Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.1","spread":null},{"groupId":"OG001","value":"157.3","spread":null},{"groupId":"OG002","value":"153.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176.9","spread":null},{"groupId":"OG001","value":"184.5","spread":null},{"groupId":"OG002","value":"170.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"719.6","spread":null},{"groupId":"OG001","value":"743.4","spread":null},{"groupId":"OG002","value":"698.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":null},{"groupId":"OG001","value":"84.2","spread":null},{"groupId":"OG002","value":"74.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 18 Months Postdose 3 in the Base Study","description":"Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"71.3","spread":null},{"groupId":"OG002","value":"69.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"82.5","spread":null},{"groupId":"OG002","value":"73.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"278.9","spread":null},{"groupId":"OG001","value":"287.3","spread":null},{"groupId":"OG002","value":"271.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"31.0","spread":null},{"groupId":"OG002","value":"26.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 30 Months Postdose 3 in the Base Study","description":"Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"80.5","spread":null},{"groupId":"OG002","value":"81.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null},{"groupId":"OG001","value":"85.3","spread":null},{"groupId":"OG002","value":"77.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"285.7","spread":null},{"groupId":"OG001","value":"296.2","spread":null},{"groupId":"OG002","value":"276.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"32.2","spread":null},{"groupId":"OG002","value":"27.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 42 Months Postdose 3 in the Base Study","description":"Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"59.6","spread":null},{"groupId":"OG002","value":"62.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null},{"groupId":"OG001","value":"69.7","spread":null},{"groupId":"OG002","value":"62.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202.1","spread":null},{"groupId":"OG001","value":"213.4","spread":null},{"groupId":"OG002","value":"192.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"25.3","spread":null},{"groupId":"OG002","value":"21.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 66 Months Postdose 3 in the Base Study","description":"Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"60.7","spread":null},{"groupId":"OG002","value":"67.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"68.9","spread":null},{"groupId":"OG002","value":"61.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219.5","spread":null},{"groupId":"OG001","value":"220.3","spread":null},{"groupId":"OG002","value":"218.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"22.8","spread":null},{"groupId":"OG002","value":"19.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 90 Months Postdose 3 in the Base Study","description":"Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"56.1","spread":null},{"groupId":"OG002","value":"57.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":null},{"groupId":"OG001","value":"49.6","spread":null},{"groupId":"OG002","value":"43.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168.3","spread":null},{"groupId":"OG001","value":"174.1","spread":null},{"groupId":"OG002","value":"164.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null},{"groupId":"OG001","value":"19.1","spread":null},{"groupId":"OG002","value":"17.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 114 Months Postdose 3 in the Base Study","description":"Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"45.7","spread":null},{"groupId":"OG002","value":"47.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":null},{"groupId":"OG001","value":"45.2","spread":null},{"groupId":"OG002","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.9","spread":null},{"groupId":"OG001","value":"147.0","spread":null},{"groupId":"OG002","value":"136.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"16.6","spread":null},{"groupId":"OG002","value":"15.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Seropositive for Anti-HPV Antibody at 1 Month Postdose 3 in the Base Study","description":"Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were \\>20 for Type 6, \\>16 for Type 11, \\>20 for Type 16, and \\>24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"98.7","spread":null},{"groupId":"OG002","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"98.5","spread":null},{"groupId":"OG002","value":"97.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null},{"groupId":"OG001","value":"98.3","spread":null},{"groupId":"OG002","value":"96.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Seropositive for Anti-HPV Antibody at 6 Months Postdose 3 in the Base Study","description":"Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were \\>20 for Type 6, \\>16 for Type 11, \\>20 for Type 16, and \\>24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"98.6","spread":null},{"groupId":"OG002","value":"98.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"99.3","spread":null},{"groupId":"OG002","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"99.8","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":null},{"groupId":"OG001","value":"86.1","spread":null},{"groupId":"OG002","value":"83.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Seropositive for Anti-HPV Antibody at 18 Months Postdose 3 in the Base Study","description":"Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were \\>20 for Type 6, \\>16 for Type 11, \\>20 for Type 16, and \\>24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null},{"groupId":"OG001","value":"89.5","spread":null},{"groupId":"OG002","value":"89.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"94.0","spread":null},{"groupId":"OG002","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":null},{"groupId":"OG001","value":"96.9","spread":null},{"groupId":"OG002","value":"96.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.6","spread":null},{"groupId":"OG001","value":"57.4","spread":null},{"groupId":"OG002","value":"52.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Seropositive for Anti-HPV Antibody at 30 Months Postdose 3 in the Base Study","description":"Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were \\>20 for Type 6, \\>16 for Type 11, \\>20 for Type 16, and \\>24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.5","spread":null},{"groupId":"OG001","value":"92.0","spread":null},{"groupId":"OG002","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"96.7","spread":null},{"groupId":"OG002","value":"94.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"98.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"58.7","spread":null},{"groupId":"OG002","value":"52.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Seropositive for Anti-HPV Antibody at 42 Months Postdose 3 in the Base Study","description":"Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were \\>20 for Type 6, \\>16 for Type 11, \\>20 for Type 16, and \\>24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.6","spread":null},{"groupId":"OG001","value":"86.2","spread":null},{"groupId":"OG002","value":"85.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null},{"groupId":"OG001","value":"93.8","spread":null},{"groupId":"OG002","value":"90.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":null},{"groupId":"OG001","value":"97.8","spread":null},{"groupId":"OG002","value":"97.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","spread":null},{"groupId":"OG001","value":"50.7","spread":null},{"groupId":"OG002","value":"45.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Seropositive for Anti-HPV Antibody at 66 Months Postdose 3 in the Base Study","description":"Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were \\>20 for Type 6, \\>16 for Type 11, \\>20 for Type 16, and \\>24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"89.4","spread":null},{"groupId":"OG002","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null},{"groupId":"OG001","value":"94.4","spread":null},{"groupId":"OG002","value":"90.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null},{"groupId":"OG001","value":"97.5","spread":null},{"groupId":"OG002","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"48.5","spread":null},{"groupId":"OG002","value":"42.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Seropositive for Anti-HPV Antibody at 90 Months Postdose 3 in the Base Study","description":"Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were \\>20 for Type 6, \\>16 for Type 11, \\>20 for Type 16, and \\>24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.7","spread":null},{"groupId":"OG001","value":"85.0","spread":null},{"groupId":"OG002","value":"84.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"90.7","spread":null},{"groupId":"OG002","value":"80.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"95.8","spread":null},{"groupId":"OG002","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":null},{"groupId":"OG001","value":"41.3","spread":null},{"groupId":"OG002","value":"39.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Seropositive for Anti-HPV Antibody at 114 Months Postdose 3 in the Base Study","description":"Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were \\>20 for Type 6, \\>16 for Type 11, \\>20 for Type 16, and \\>24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null},{"groupId":"OG001","value":"79.0","spread":null},{"groupId":"OG002","value":"78.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"86.7","spread":null},{"groupId":"OG002","value":"83.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.9","spread":null},{"groupId":"OG001","value":"95.0","spread":null},{"groupId":"OG002","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","spread":null},{"groupId":"OG001","value":"38.9","spread":null},{"groupId":"OG002","value":"33.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence Rate of HPV 6/11 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer","description":"HPV 6/11: The two types of HPV (types 6/11) were determined by PCR testing","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of HPV 6/11-related Condyloma: Day 1 to Year 4","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Day 1 to Year 4 conditional on having been event-free at Day 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null},{"groupId":"OG001","value":"0.0055","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of HPV 6/11-related Condyloma: Year 4 to Year 8","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 4 to Year 8 conditional on having been event-free from Day 1 to Year 4. The analysis windows were cut at the exact time points, e.g., Year 4. Visits and events which occurred after Year 4 due to visit window or follow-up investigations are included in the Year 4 to Year 8 time interval.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of HPV 6/11-related Condyloma: Year 6 to Year 10","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 6 to Year 10 conditional on having been event-free from Day 1 to Year 6.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence Rate of HPV 6/11-related Condyloma (Secondary Analysis): Day 1 to Year 4","description":"The four HPV types were determined by PCR testing.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence Rate of HPV 6/11-related Condyloma (Secondary Analysis): Year 4 to Year 8","description":"The four HPV types were determined by PCR testing. The analysis windows were cut at the exact time points, e.g., Year 4. Visits and events which occurred after Year 4 due to visit window or follow-up investigations are included in the Year 4 to Year 8 time interval.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence Rate of HPV 6/11-related Condyloma (Secondary Analysis): Year 6 to Year 10","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 6 to Year 10 conditional on having been event-free from Day 1 to Year 6.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence Rate of HPV 31/33/35/52/58 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer","description":"This outcome measure was not analyzed because of diminished interest by experts in composite efficacy endpoints associated with these HPV types","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of HPV 16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer","description":"HPV 16/18: The two types of HPV (types 16/18) were determined by PCR testing","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Incidence of HPV 16/18-related CIN 2 or Worse: Day 1 to Year 4","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Day 1 to Year 4 conditional on having been event-free at Day 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0007","spread":null},{"groupId":"OG001","value":"0.0041","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Incidence of HPV 16/18-related CIN 2 or Worse: Year 4 to 8","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 4 to Year 8 conditional on having been event-free from Day 1 to Year 4. The analysis windows were cut at the exact time points, e.g., Year 4. Visits and events which occurred after Year 4 due to visit window or follow-up investigations are included in the Year 4 to Year 8 time interval.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cumulative Incidence of HPV 16/18-related CIN 2 or Worse: Year 6 to 10","description":"The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 6 to Year 10 conditional on having been event-free from Day 1 to Year 6.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of HPV 16/18-related CIN 2 or Worse (Secondary Analysis): Day 1 to Year 4","description":"The four HPV types were determined by PCR testing.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of HPV 16/18-related CIN 2 or Worse (Secondary Analysis): Year 4 to 8","description":"The four HPV types were determined by PCR testing. The analysis windows were cut at the exact time points, e.g., Year 4. Visits and events which occurred after Year 4 due to visit window or follow-up investigations are included in the Year 4 to Year 8 time interval.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of HPV 16/18-related CIN 2 or Worse (Secondary Analysis): Year 6 to 10","description":"The four HPV types were determined by PCR testing.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":1890},"commonTop":["Injection site pain","Headache","Injection site swelling","Injection site erythema","Pyrexia"]}}}